Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | February 28, 2017 | March 02, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 28, 2017 · Filed March 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 69,240 |
Reported balance
After 2017-02-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-02-28 · Grant · Acquired 26,367 · Balance 69,240 F1: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. F2: Due to administrative error, the Form 4 previously filed on January 6, 2017 over-reported the shares acquired by 1 share. This Form 4 reflects the corrected total beneficial ownership for this reporting person. |
| Common shares without par valueSEC Table I · non-derivative | Direct | 60,359 |
Reported balance
After 2017-02-28 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2017-02-28 · Tax withholding · Disposed 8,881 · Balance 60,359 |
| Common shares without par valueSEC Table I · non-derivative | Direct | 56,508 |
Reported balance
After 2017-03-01 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2017-03-01 · Sale · Disposed 3,851 · Balance 56,508 |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Trust | 39,413 |
Reported balance
Holding disclosure · report date 2017-02-28 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 39,413 F3: Held in the Stefanie M. Warmuth Revocable Trust. The reporting person and his spouse are trustees of the trust. The trust is revocable by the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities. |
Filing footnotes · ownership attribution and instrument terms
F1: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3.
F2: Due to administrative error, the Form 4 previously filed on January 6, 2017 over-reported the shares acquired by 1 share. This Form 4 reflects the corrected total beneficial ownership for this reporting person.
F3: Held in the Stefanie M. Warmuth Revocable Trust. The reporting person and his spouse are trustees of the trust. The trust is revocable by the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 13, 2012 Filed Sep 17, 2012 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 2,923 | $0.00 Strike: $67.84 | $0.00 |
DisclosureSEC source: 0001179110-12-014150 · edgar.xml · derivative · entry 5 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,923 Underlying: Common shares · 2,923 shares Expires 2014-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 13, 2012 Filed Sep 17, 2012 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 3,368 | $0.00 Strike: $54.05 | $0.00 |
DisclosureSEC source: 0001179110-12-014150 · edgar.xml · derivative · entry 4 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 3,368 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 13, 2012 Filed Sep 17, 2012 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,923 | $67.84 | $198,296.32 |
DisclosureSEC source: 0001179110-12-014150 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,070 Read SEC document |
| September 13, 2012 Filed Sep 17, 2012 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 3,368 | $54.05 | $182,040.40 |
DisclosureSEC source: 0001179110-12-014150 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2012 Filed Aug 17, 2012 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 9,400 | $0.00 Strike: $44.16 | $0.00 |
DisclosureSEC source: 0001179110-12-013059 · edgar.xml · derivative · entry 6 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 9,400 shares Expires 2016-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 16, 2012 Filed Aug 17, 2012 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 5,553 | $66.48 | $369,163.44 |
DisclosureSEC source: 0001179110-12-013059 · edgar.xml · nonDerivative · entry 4 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,625 Read SEC document |
| August 16, 2012 Filed Aug 17, 2012 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,900 | $66.47 | $126,293.00 |
DisclosureSEC source: 0001179110-12-013059 · edgar.xml · nonDerivative · entry 3 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,178 Read SEC document |
| August 16, 2012 Filed Aug 17, 2012 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,947 | $66.46 | $129,397.62 |
DisclosureSEC source: 0001179110-12-013059 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,078 Read SEC document |
| August 16, 2012 Filed Aug 17, 2012 21:10 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 9,400 | $44.16 | $415,104.00 |
DisclosureSEC source: 0001179110-12-013059 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 5,404 | $0.00 Strike: $66.39 | $0.00 |
DisclosureSEC source: 0001179110-12-012181 · edgar.xml · derivative · entry 5 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,404 Underlying: Common shares · 5,404 shares Expires 2014-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 6,274 | $0.00 Strike: $52.23 | $0.00 |
DisclosureSEC source: 0001179110-12-012181 · edgar.xml · derivative · entry 4 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 6,274 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 5,404 | $66.39 | $358,771.56 |
DisclosureSEC source: 0001179110-12-012181 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,625 Read SEC document |
| July 30, 2012 Filed Aug 1, 2012 21:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 6,274 | $52.23 | $327,691.02 |
DisclosureSEC source: 0001179110-12-012181 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2012 Filed Jul 25, 2012 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 3,103 | $0.00 Strike: $65.06 | $0.00 |
DisclosureSEC source: 0001179110-12-011781 · edgar.xml · derivative · entry 5 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,103 Underlying: Common shares · 3,103 shares Expires 2014-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 23, 2012 Filed Jul 25, 2012 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 3,572 | $0.00 Strike: $51.91 | $0.00 |
DisclosureSEC source: 0001179110-12-011781 · edgar.xml · derivative · entry 4 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 3,572 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| July 23, 2012 Filed Jul 25, 2012 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,103 | $65.06 | $201,881.18 |
DisclosureSEC source: 0001179110-12-011781 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,755 Read SEC document |
| July 23, 2012 Filed Jul 25, 2012 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 3,572 | $51.91 | $185,422.52 |
DisclosureSEC source: 0001179110-12-011781 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,858 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2012 Filed Apr 3, 2012 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 6,146 | $0.00 Strike: $54.05 | $0.00 |
DisclosureSEC source: 0001179110-12-006284 · edgar.xml · derivative · entry 8 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 6,146 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 30, 2012 Filed Apr 3, 2012 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,649 | $0.00 Strike: $57.93 | $0.00 |
DisclosureSEC source: 0001179110-12-006284 · edgar.xml · derivative · entry 7 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 2,649 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 30, 2012 Filed Apr 3, 2012 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 4,540 | $0.00 Strike: $54.03 | $0.00 |
DisclosureSEC source: 0001179110-12-006284 · edgar.xml · derivative · entry 6 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 4,540 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| March 30, 2012 Filed Apr 3, 2012 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 13,335 | $61.16 | $815,568.60 |
DisclosureSEC source: 0001179110-12-006284 · edgar.xml · nonDerivative · entry 4 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,286 Read SEC document |
| March 30, 2012 Filed Apr 3, 2012 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 6,146 | $54.05 | $332,191.30 |
DisclosureSEC source: 0001179110-12-006284 · edgar.xml · nonDerivative · entry 3 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2012 Filed Apr 3, 2012 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,649 | $57.93 | $153,456.57 |
DisclosureSEC source: 0001179110-12-006284 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2012 Filed Apr 3, 2012 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 4,540 | $54.03 | $245,296.20 |
DisclosureSEC source: 0001179110-12-006284 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,826 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2012 Filed Mar 14, 2012 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 13,500 | $0.00 Strike: $46.34 | $0.00 |
DisclosureSEC source: 0001179110-12-005027 · edgar.xml · derivative · entry 5 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 13,500 shares Expires 2015-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| March 12, 2012 Filed Mar 14, 2012 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 11,590 | $57.95 | $671,640.50 |
DisclosureSEC source: 0001179110-12-005027 · edgar.xml · nonDerivative · entry 3 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,286 Read SEC document |
| March 12, 2012 Filed Mar 14, 2012 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 13,500 | $46.34 | $625,590.00 |
DisclosureSEC source: 0001179110-12-005027 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,876 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2012 Filed Mar 14, 2012 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 25,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-005027 · edgar.xml · nonDerivative · entry 4 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 25,337 F1 · balance_after: Held in the Stefanie M. Warmuth Revocable Trust. The reporting person and his spouse are trustees of the trust. The trust is revocable by the reporting person's spouse. The reporting person disclaims beneficial ownership of these securities. Read SEC document |
| March 07, 2012 Filed Mar 14, 2012 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 25,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-005027 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,376 Read SEC document |
| March 01, 2012 Filed Mar 2, 2012 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,059 | $56.72 | $116,786.48 |
DisclosureSEC source: 0001179110-12-004079 · edgar.xml · nonDerivative · entry 9 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,641 Read SEC document |
| March 01, 2012 Filed Mar 2, 2012 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 2,952 | $56.73 | $167,466.96 |
DisclosureSEC source: 0001179110-12-004079 · edgar.xml · nonDerivative · entry 8 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,700 Read SEC document |
| March 01, 2012 Filed Mar 2, 2012 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 352 | $56.74 | $19,972.48 |
DisclosureSEC source: 0001179110-12-004079 · edgar.xml · nonDerivative · entry 7 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,652 Read SEC document |
| March 01, 2012 Filed Mar 2, 2012 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 7,048 | $56.75 | $399,974.00 |
DisclosureSEC source: 0001179110-12-004079 · edgar.xml · nonDerivative · entry 6 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,004 Read SEC document |
| March 01, 2012 Filed Mar 2, 2012 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,700 | $56.76 | $96,492.00 |
DisclosureSEC source: 0001179110-12-004079 · edgar.xml · nonDerivative · entry 5 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,052 Read SEC document |
| March 01, 2012 Filed Mar 2, 2012 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $56.76 | $11,352.20 |
DisclosureSEC source: 0001179110-12-004079 · edgar.xml · nonDerivative · entry 4 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,752 Read SEC document |
| March 01, 2012 Filed Mar 2, 2012 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 4,145 | $56.77 | $235,311.65 |
DisclosureSEC source: 0001179110-12-004079 · edgar.xml · nonDerivative · entry 3 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,952 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 9,077 | $57.04 | $517,752.08 |
DisclosureSEC source: 0001179110-12-004079 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,097 Read SEC document |
| February 29, 2012 Filed Mar 2, 2012 22:20 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 10,834 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-12-004079 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,174 F1 · shares: Settlement of a performance-based restricted stock unit in shares in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 17, 2012 Filed Feb 22, 2012 23:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 48,100 | $0.00 Strike: $56.26 | $0.00 |
DisclosureSEC source: 0001179110-12-003237 · edgar.xml · derivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,100 Underlying: Common shares · 48,100 shares Expires 2022-02-16 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,034 on 02/17/2013, 16,033 on 02/17/2014, and 16,033 on 02/17/2015. Read SEC document |
| December 21, 2011 Filed Dec 23, 2011 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 14,363 | $0.00 Strike: $53.63 | $0.00 |
DisclosureSEC source: 0001179110-11-017127 · edgar.xml · derivative · entry 4 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 14,363 shares Expires 2012-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 21, 2011 Filed Dec 23, 2011 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 14,363 | $55.00 | $789,965.00 |
DisclosureSEC source: 0001179110-11-017127 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,340 Read SEC document |
| December 21, 2011 Filed Dec 23, 2011 22:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 14,363 | $53.63 | $770,215.88 |
DisclosureSEC source: 0001179110-11-017127 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2011 Filed Dec 16, 2011 22:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,094 | $54.23 | $59,327.62 |
DisclosureSEC source: 0001179110-11-016819 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,340 Read SEC document |
| June 03, 2011 Filed Jun 3, 2011 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 91 | $51.13 | $4,652.83 |
DisclosureSEC source: 0001179110-11-009245 · edgar.xml · nonDerivative · entry 6 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,434 Read SEC document |
| June 01, 2011 Filed Jun 3, 2011 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,600 | $51.92 | $342,678.60 |
DisclosureSEC source: 0001179110-11-009245 · edgar.xml · nonDerivative · entry 5 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,525 Read SEC document |
| June 01, 2011 Filed Jun 3, 2011 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 6,020 | $51.92 | $312,558.40 |
DisclosureSEC source: 0001179110-11-009245 · edgar.xml · nonDerivative · entry 4 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,125 Read SEC document |
| June 01, 2011 Filed Jun 3, 2011 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $51.92 | $10,384.08 |
DisclosureSEC source: 0001179110-11-009245 · edgar.xml · nonDerivative · entry 3 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,145 Read SEC document |
| June 01, 2011 Filed Jun 3, 2011 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $51.92 | $10,384.06 |
DisclosureSEC source: 0001179110-11-009245 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,345 Read SEC document |
| June 01, 2011 Filed Jun 3, 2011 21:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 200 | $51.92 | $10,384.10 |
DisclosureSEC source: 0001179110-11-009245 · edgar.xml · nonDerivative · entry 1 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,545 Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 22:13 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,121 | $48.32 | $54,170.08 |
DisclosureSEC source: 0001179110-11-003917 · edgar.xml · nonDerivative · entry 2 Warmuth Michael J · CIK 0001452290 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,745 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.